Home Latest Articles
Latest Articles
  • Hong CHEN, Zhuhui ZHAO, Guomei SHEN, Lijun ZHOU, Xiaowen ZHAI
    World Clinical Drug. 2022, 43(10): 1227-1232.

    A hospital designed a medication log based on the guiding principles of clinical application of antibiotics. The items filled in the log included symptoms, signs and examination results of children, so as to comprehensively reflect the basis of doctors' prescriptions. Taking into account the non-medical factors affecting doctors' prescriptions, the reasons for prescribing were added in the log, such as the need for illness, the experience of medication, and the request of family members. The logs were filled in by physicians independently, and the results were counted regularly by specially-assigned personnel, and the medication situation was summarized and analyzed at the regular meeting of the department, and rectification suggestions were put forward. After the using the log, the hospital obtained the data of irrational drug use for different reasons in pediatric outpatient department for the first time, which clarified the direction of improvement. Doctors' awareness of rational drug use was improved and their self-discipline was strengthened. Medication management efficiency improved. In the future, the hospital will continue to implement medication log and promote it to other outpatient departments, accelerate the construction of electronic medical records, embed the electronic log into the doctor's workstation, and optimize medication assessment.

  • Guomei SHEN, Xuan GAO, Lijun ZHOU, Jie XU, Hui XU, Junhua TIAN, Xiaowen ZHAI
    World Clinical Drug. 2022, 43(10): 1233-1240.

    At present, the irrational use of antimicrobial agents and the drug-resistance of bacteria are severe problems in the world. Based on the successful cases of scientific antimicrobial stewardship (AMS) in children's hospital of Fudan university, we continued to collect the key problems in promoting the rational use of antimicrobial agents and sort out the reasons of unreasonable use. This study aimed to carry out relevant research on the implementation of personalized intervention measures in the terms of parents' awareness of antibiotic usage, investigation and analysis of doctors' prescription behavior, strengthening the performance management of doctors and keeping a log of the records of usage of antimicrobial agents in four members of Fudan Pediatric Medical Alliance, and to encourage all medical alliances to explore and establish scientific AMS suitable for themselves.

  • Silei YAN, Xiaoyan DONG
    World Clinical Drug. 2022, 43(10): 1241-1248.

    Lower respiratory tract infection is the most common infectious disease in children, its pathogenic microorganisms mainly include bacteria, viruses, mycoplasma, chlamydia, Mycobacterium tuberculosis and so on. In recent years, the widespread use of antibiotics, made the drug-resistant bacteria constantly emerging, which brings great challenges to clinical anti-infection treatment. This present article reviewed the drug resistance of pathogens in children with lower respiratory tract infection, in order to provide reference or inspiration for clinicians to treat children lower respiratory tract infection.

  • Gang YU, Hailin ZHANG
    World Clinical Drug. 2022, 43(10): 1249-1254.

    Lower respiratory tract infections in children are the leading cause of hospitalization in children and the leading cause of children's death worldwide. The pathogen spectrum of lower respiratory tract infections includes viruses, bacteria, mycoplasma pneumoniae, fungi and so on. Coinfections are common. The younger, the sicker, or the host with immunodeficiency, the greater the risk of coinfections. Children with coinfections are more difficult to treat and may have a worse prognosis than those with Single-pathogen infection. Pediatricians should pay attention to the combined application of antibacterials in children with lower respiratory tract coinfection.

  • Weijian ZHANG, Hanmin LIU
    World Clinical Drug. 2022, 43(10): 1255-1261.

    Respiratory diseases are the most common diseases in childhood. Macrolides, which are often used as antibiotics, show immunomodulatory effects in clinical use and have certain effect on childhood respiratory diseases, with uncertain mechanism. This review focuses on immunomodulatory effects of macrolides on the prognosis of childhood respiratory diseases.

  • Qianqian FU, Yuanyuan QI, Xiaobo ZHANG
    World Clinical Drug. 2022, 43(10): 1262-1268.

    Children are the particular group during clinical treatments, with rapid and immature physical development and largely individual differences. In recent years, unreasonable usage of antibacterial drugs for children is a serious problem. The antimicrobials pharmacokinetic/pharmacodynamic (PK/PD) model and its parameters can provide evidence for antimicrobial use in children, which benefits for rational use of antibiotics in children and optimizies the clinical individualized drug delivery schemes.

  • Jinyan TANG, Ruixin WANG, xuanxuan YAN, Yiqing WANG, Xiaohua YING
    World Clinical Drug. 2022, 43(10): 1269-1276.

    Cost-effectiveness threshold (CET) can judge the economy efficiency of different medical intervention measures. It is an important reference standard for medical insurance directory access. It is also an important pharmacoeconomic evidence for the lack of medical insurance access negotiations for innovative drugs in China. This paper summarizes the experience of the application of CET in the world and lays a foundation for the determination and application of innovative drug CET in China. CET is an important basis for the selection of health interventions in many countries. It is mainly divided into implicit threshold and explicit threshold, most countries use implicit threshold for decision-making. The per capita GDP multiple is the CET mode selected by most countries. In the face of different application scenarios of innovative drugs, such as rare diseases treatment, end-stage treatment and disease treatment of different severity, countries make adjustments to different degrees on the basis of general CET. It is not clear whether CET is used in China's health decision-making. It is suggested to explore the threshold and level in line with China's national conditions on the basis of international experience, focus on exploring the application of hidden threshold in medical insurance access and preferential policies for rare diseases and end-of-life drugs and actively promote the scientific determination of CET in China.

  • Ruoting WANG, Jianfeng LI, Jingyi ZHANG, Guowei LI
    World Clinical Drug. 2022, 43(10): 1277-1282.

    Randomized controlled trials (RCT) of direct comparisons are the gold standard for assessing comparative treatment effects between different interventions. When it is not feasible to conduct a direct comparative RCT due to ethical and economic reasons, the published clinical research evidence and available data can be used to indirectly compare different interventions. However, the commonly used indirect comparison methods deal with the effectineness and safety the efficacy of different interventions separately, potentially leading to difficulty in decision-making caused by the inconsistency between the effectivencess and safety. The number needed to treat for net effect (NNTnet), as a novel indirect comparison method can synthetically assess the comparative treatment effects of different interventions by combining their efficacy and safety simultaneously. The NNTnet can provide important referance and evidence support for health professionals, researchers and resource managers to make scientific decisions in clinical practice.

  • Yitian LANG, Xiaoyan LIU, Bin WU
    World Clinical Drug. 2022, 43(10): 1283-1291.
    Objectives

    Due to the unique mechanism of immunotherapy, the shape of its survival curve differs from that of conventional treatment. In order to better understand the causes of this type of survival curve and how to optimize the long-term simulation survival curves of immunotherapy, this study provides an introduction and an example demonstration to serve as a reference for relevant researchers.

    Method

    Taking the survival data of Checkmate-067 trial as an example, different survival models are used to extrapolate the survival data based on 0 to 27 months, and the results of extrapolated curve are compared with the actual survival curve of 28 to 60 months.

    Results

    In this example, the shape of overall survival curve is consistent with the conventional shape, and it is well fitted with different survival models, but the shape of progression free survival (PFS) curve with immunotherapy is significantly different from that with conventional therapy, and the fit is poor.

    Conclusion

    For the long-term survival simulation of immunotherapy, it is not recommended to select the model only considering the Akaike information criteria and Bayesian information criteria. Moreover, it is necessary to optimize the model based on the characteristics of immunotherapy, and making the corresponding fitting curve as far as possible for visual inspection. Also, the curve fitting requires special optimization or selection of a more flexible survival model when encountering the pseudo-progression or plateau.

  • Qingqiang LEI, Zixuan HE, Min HU, Wen CHEN
    World Clinical Drug. 2022, 43(10): 1292-1298.

    Indication expansion is a common situation we ofter face in the dynamic adjustment of the national medical insurance drug list in China. This study reviewed the experiences of drug price adjustment in typical countries under the condition of indication expansion and summarized the enlightenment to China. Typical countries took variable measures to determine the drug prices after the expansion of new indications such as access after evaluations by indications based on list prices, weighted pricing method based on value and sales, volume-price drug pricing, indication-based pricing based on risk sharing agreements, and drug pricing based on evaluations in the initial access process. Different approaches have different impacts on protecting the financial risk of the medical insurance funds, encouraging research and development and innovation in the pharmaceutical industry, and ensuring the drug accessibility for the insured patients with new indications. We should clarify the main problems and challenges of medical insurance management in the current stage in China, draw on useful experiences, and improve the price adjustment strategies of medical insurance drugs in the case of indication expansion.

News